Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.
Pepaxto might not be a complete bust in myeloma.
Upon review Pepaxto beats Pomalyst on progression-free survival, but new overall survival data trigger clinical hold and threaten the programme.
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
Demand for new issues remains sluggish - only eight private biotechs managed to pull off an IPO in the first quarter of 2017.